Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Mol Sci ; 22(21)2021 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-34769291

RESUMEN

Omega-3 polyunsaturated fatty acids (n-3 PUFAs) play an important role in the development, maintenance, and function of the brain. Dietary supplementation of n-3 PUFAs in neurological diseases has been a subject of particular interest in preventing cognitive deficits, and particularly in age-related neurodegeneration. Developing strategies for the efficient delivery of these lipids to the brain has presented a challenge in recent years. We recently reported the preparation of n-3 PUFA-rich nanoliposomes (NLs) from salmon lecithin, and demonstrated their neurotrophic effects in rat embryo cortical neurons. The objective of this study was to assess the ability of these NLs to deliver PUFAs in cellulo and in vivo (in mice). NLs were prepared using salmon lecithin rich in n-3 PUFAs (29.13%), and characterized with an average size of 107.90 ± 0.35 nm, a polydispersity index of 0.25 ± 0.01, and a negative particle-surface electrical charge (-50.4 ± 0.2 mV). Incubation of rat embryo cortical neurons with NLs led to a significant increase in docosahexaenoic acid (DHA) (51.5%, p < 0.01), as well as palmitic acid, and a small decrease in oleic acid after 72 h (12.2%, p < 0.05). Twenty mice on a standard diet received oral administration of NLs (12 mg/mouse/day; 5 days per week) for 8 weeks. Fatty acid profiles obtained via gas chromatography revealed significant increases in cortical levels of saturated, monounsaturated, and n-3 (docosahexaenoic acid,) and n-6 (docosapentaenoic acid and arachidonic acid) PUFAs. This was not the case for the hippocampus or in the liver. There were no effects on plasma lipid levels, and daily monitoring confirmed NL biocompatibility. These results demonstrate that NLs can be used for delivery of PUFAs to the brain. This study opens new research possibilities in the development of preventive as well as therapeutic strategies for age-related neurodegeneration.


Asunto(s)
Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Insaturados/sangre , Lecitinas/administración & dosificación , Neuronas/citología , Salmón/metabolismo , Administración Oral , Animales , Disponibilidad Biológica , Células Cultivadas , Cromatografía de Gases , Ácidos Docosahexaenoicos/análisis , Ácidos Grasos Omega-3/farmacocinética , Femenino , Hipocampo/química , Lecitinas/farmacocinética , Liposomas , Hígado/química , Masculino , Ratones , Nanoestructuras , Neuronas/química , Ácido Oléico/análisis , Ácido Palmítico/análisis , Tamaño de la Partícula , Cultivo Primario de Células , Ratas
2.
Int J Mol Sci ; 21(10)2020 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-32414043

RESUMEN

Investigations in cartilage biology have been hampered by the limited capacity of chondrocytes, especially in rats and humans, to be efficiently transfected. Liposomes are a promising delivery system due to their lipid bilayer structure similar to a biological membrane. Here we used natural rapeseed lecithin, which contains a high level of mono- and poly-unsaturated fatty acids, to evaluate the cytocompatibility of these phospholipids as future potential carriers of biomolecules in joint regenerative medicine. Results show that appropriate concentrations of nanoliposome rapeseed lecithin under 500 µg/mL were safe for chondrocytes and did not induce any alterations of their phenotype. Altogether, these results sustain that they could represent a novel natural carrier to deliver active substances into cartilage cells.


Asunto(s)
Cartílago Articular/crecimiento & desarrollo , Condrocitos/efectos de los fármacos , Liposomas/farmacología , Nanopartículas/química , Animales , Brassica napus/química , Cartílago Articular/efectos de los fármacos , Membrana Celular/genética , Sistemas de Liberación de Medicamentos , Humanos , Lecitinas/química , Lecitinas/genética , Lecitinas/farmacología , Liposomas/química , Fosfolípidos/genética , Ratas , Medicina Regenerativa
3.
Mar Drugs ; 18(4)2020 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-32316578

RESUMEN

Current anticancer drugs exhibit limited efficacy and initiate severe side effects. As such, identifying bioactive anticancer agents that can surpass these limitations is a necessity. One such agent, curcumin, is a polyphenolic compound derived from turmeric, and has been widely investigated for its potential anti-inflammatory and anticancer effects over the last 40 years. However, the poor bioavailability of curcumin, caused by its low absorption, limits its clinical use. In order to solve this issue, in this study, curcumin was encapsulated in chitosan-coated nanoliposomes derived from three natural lecithin sources. Liposomal formulations were all in the nanometric scale (around 120 nm) and negatively charged (around -40 mV). Among the three lecithins, salmon lecithin presented the highest growth-inhibitory effect on MCF-7 cells (two times lower growth than the control group for 12 µM of curcumin and four times lower for 20 µM of curcumin). The soya and rapeseed lecithins showed a similar growth-inhibitory effect on the tumor cells. Moreover, coating nanoliposomes with chitosan enabled a higher loading efficiency of curcumin (88% for coated liposomes compared to 65% for the non-coated liposomes) and a stronger growth-inhibitory effect on MCF-7 breast cancer cells.


Asunto(s)
Antineoplásicos/farmacología , Curcumina/farmacología , Composición de Medicamentos/métodos , Sistemas de Liberación de Medicamentos/métodos , Liposomas/farmacología , Animales , Disponibilidad Biológica , Brassica rapa , Neoplasias de la Mama/tratamiento farmacológico , Quitosano , Portadores de Fármacos , Femenino , Humanos , Lecitinas , Células MCF-7 , Nanopartículas , Salmón , Células Tumorales Cultivadas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA